These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33844099)

  • 1. SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.
    Tsang JY; Lai ST; Ni YB; Shao Y; Poon IK; Kwan JS; Chow C; Shea KH; Tse GM
    Breast Cancer Res Treat; 2021 Jun; 187(2):339-347. PubMed ID: 33844099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
    Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
    Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SETD2-dependent H3K36me3 plays a critical role in epigenetic regulation of the HPV31 life cycle.
    Gautam D; Johnson BA; Mac M; Moody CA
    PLoS Pathog; 2018 Oct; 14(10):e1007367. PubMed ID: 30312361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
    Fontebasso AM; Schwartzentruber J; Khuong-Quang DA; Liu XY; Sturm D; Korshunov A; Jones DT; Witt H; Kool M; Albrecht S; Fleming A; Hadjadj D; Busche S; Lepage P; Montpetit A; Staffa A; Gerges N; Zakrzewska M; Zakrzewski K; Liberski PP; Hauser P; Garami M; Klekner A; Bognar L; Zadeh G; Faury D; Pfister SM; Jabado N; Majewski J
    Acta Neuropathol; 2013 May; 125(5):659-69. PubMed ID: 23417712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation.
    Hacker KE; Fahey CC; Shinsky SA; Chiang YJ; DiFiore JV; Jha DK; Vo AH; Shavit JA; Davis IJ; Strahl BD; Rathmell WK
    J Biol Chem; 2016 Sep; 291(40):21283-21295. PubMed ID: 27528607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SETD2 Methyltransferase Supports Productive HPV31 Replication through the LEDGF/CtIP/Rad51 Pathway.
    Mac M; DeVico BM; Raspanti SM; Moody CA
    J Virol; 2023 May; 97(5):e0020123. PubMed ID: 37154769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SETD2: an epigenetic modifier with tumor suppressor functionality.
    Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
    Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
    Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
    Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.
    Liu W; Fu Q; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
    Medicine (Baltimore); 2015 Nov; 94(45):e2004. PubMed ID: 26559293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPOP-containing complex regulates SETD2 stability and H3K36me3-coupled alternative splicing.
    Zhu K; Lei PJ; Ju LG; Wang X; Huang K; Yang B; Shao C; Zhu Y; Wei G; Fu XD; Li L; Wu M
    Nucleic Acids Res; 2017 Jan; 45(1):92-105. PubMed ID: 27614073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
    Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
    Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SETD2 histone modifier loss in aggressive GI stromal tumours.
    Huang KK; McPherson JR; Tay ST; Das K; Tan IB; Ng CC; Chia NY; Zhang SL; Myint SS; Hu L; Rajasegaran V; Huang D; Loh JL; Gan A; Sairi AN; Sam XX; Dominguez LT; Lee M; Soo KC; Ooi LL; Ong HS; Chung A; Chow PK; Wong WK; Selvarajan S; Ong CK; Lim KH; Nandi T; Rozen S; Teh BT; Quek R; Tan P
    Gut; 2016 Dec; 65(12):1960-1972. PubMed ID: 26338826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
    Hu M; Hu M; Zhang Q; Lai J; Liu X
    Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.
    Bu J; Chen A; Yan X; He F; Dong Y; Zhou Y; He J; Zhan D; Lin P; Hayashi Y; Sun Y; Zhang Y; Xiao Z; Grimes HL; Wang QF; Huang G
    Leukemia; 2018 Apr; 32(4):890-899. PubMed ID: 29249820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
    Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
    Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of functional cooperative mutations of SETD2 in human acute leukemia.
    Zhu X; He F; Zeng H; Ling S; Chen A; Wang Y; Yan X; Wei W; Pang Y; Cheng H; Hua C; Zhang Y; Yang X; Lu X; Cao L; Hao L; Dong L; Zou W; Wu J; Li X; Zheng S; Yan J; Zhou J; Zhang L; Mi S; Wang X; Zhang L; Zou Y; Chen Y; Geng Z; Wang J; Zhou J; Liu X; Wang J; Yuan W; Huang G; Cheng T; Wang QF
    Nat Genet; 2014 Mar; 46(3):287-93. PubMed ID: 24509477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability.
    Pfister SX; Ahrabi S; Zalmas LP; Sarkar S; Aymard F; Bachrati CZ; Helleday T; Legube G; La Thangue NB; Porter AC; Humphrey TC
    Cell Rep; 2014 Jun; 7(6):2006-18. PubMed ID: 24931610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H3K36 trimethylation mediated by SETD2 regulates the fate of bone marrow mesenchymal stem cells.
    Wang L; Niu N; Li L; Shao R; Ouyang H; Zou W
    PLoS Biol; 2018 Nov; 16(11):e2006522. PubMed ID: 30422989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.
    Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH
    Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer.
    Kumari S; Muthusamy S
    Eur J Cancer Prev; 2020 Nov; 29(6):556-564. PubMed ID: 33021769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.